IP Library › Patent Application 10653387
Patent Application
App. No. 10/653,387

Method of determining a chemotherapeutic regimen based on glutathione-s-transferase pi expression

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/653,387
Abstract

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing GST-pi expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance or sensitivity of a patient's tumor to treatment with platinum-based therapies by examination of the amount of GST-pi mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair GST-piand methods comprising their use for detecting levels of GST-pi mRNA.

Claims (29)

1 . (cancel)

2 . (cancel)

3 . (cancel)

4 . (cancel)

5 . (cancel)

6 . (cancel)

7 . (cancel)

8 . (cancel)

9 . (cancel)

10 . (cancel)

11 . (cancel)

12 . (cancel)

13 . (cancel)

14 . (cancel)

15 . A method for determining a platinum-based chemotherapeutic regimen for treating a tumor in a patient comprising:

(a) obtaining a tissue sample of the tumor and fixing the sample, to obtain a fixed tumor sample;

(b) isolating mRNA from the fixed tumor sample by heating the fixed tumor sample in the presence of an effective concentration of a chaotropic agent wherein the heating occurs at a temperature from about 75° C. to about 100° C. for a time period of about 5 to about 120 minutes;

(c) subjecting the mRNA to amplification using a pair of oligonucleotide primers capable of amplifying a region of the GST-pi gene, to obtain an amplified sample;

(d) determining the amount of GST-pi mRNA in the amplified sample;

(e) comparing the amount of GST-pi mRNA from step (d) to an amount of mRNA of an internal control gene to obtain a relative GST-pi expression level; and

(f) determining a platinum-based chemotherapeutic regimen based on the relative GST-pi expression level in the amplified sample and a predetermined threshold level for GST-pi gene expression.

16 . The method of claim 15 wherein the tumor is an esophogeal adenocarcinaoma tumor.

17 . A method for determining a platinum-based chemotherapeutic regimen for treating a tumor in a patient comprising:

(a) obtaining a tissue sample of the tumor and fixing the sample, to obtain a fixed tumor sample;

(b) isolating mRNA from the fixed tumor sample by heating the fixed tumor sample in the presence of an effective concentration of a chaotropic agent wherein the heating occurs at a temperature from about 75° C. to about 100° C. for a time period of about 5 to about 120 minutes;

(c) determining the amount of GST-pi mRNA in the fixed tumor sample;

(d) comparing the amount of GST-pi mRNA from step (c) to an amount of mRNA of an internal control gene in the fixed tumor sample to obtain a relative GST-pi expression level; and

(e) determining a platinum-based chemotherapeutic regimen based on the relative GST-pi expression level in the fixed tumor sample and a predetermined threshold level for GST-pi gene expression.

18 . The method of claim 17 wherein the tumor is an esophageal adenocarcinoma tumor.